基于模型调整ATG剂量在体外CD34+筛选异基因造血细胞移植中的2期研究
这项单中心、单臂2期试验在清髓性预处理后接受体外CD34+筛选异基因造血细胞移植的血液恶性肿瘤患者中,用药代动力学模型将移植后ATG暴露控制在<20 AU×d/mL。56例可评估患者中70%达到CD4+免疫重建的主要终点,中位ATG暴露为10 AU×d/mL。
要点
- 模型指导ATG剂量使70%患者在第100天前实现CD4+免疫重建。
- 中位移植后ATG暴露为10 AU×d/mL,低于目标上限20 AU×d/mL。
- 3级及以上不良事件以感染和口腔/胃肠道事件最常见。
核心结论
- 基于模型调整ATG剂量可促进体外CD34+筛选异基因造血细胞移植后的CD4+免疫重建。
研究设计与样本
- 单中心、单臂2期试验,2021年6月14日至2023年11月28日入组59例血液恶性肿瘤患者,可评估56例。
主要发现
- 56例可评估患者中39例(70%)达到CD4+免疫重建(第+100天前连续两次>50 cells/μL)。
- 移植后中位估计ATG暴露为10 AU×d/mL(IQR 9-11)。
- 259例次3级及以上不良事件中,感染103例次(40%),口腔或胃肠道事件44例次(17%)。
- 3例发生5级不良事件,包括继发性植入失败1例和多器官衰竭2例,共4例治疗相关死亡。
关键数值与推荐
- ATG目标为移植后暴露<20 AU×d/mL。
- 主要终点为符合方案人群中至少32%在第+100天前连续两次CD4+>50 cells/μL。
临床怎么用
- 在清髓性、不含钙调神经磷酸酶抑制剂的体外CD34+筛选移植中,可考虑药代动力学模型指导ATG给药以优化免疫恢复。
局限性
- 单中心、单臂设计,样本量有限,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ex-vivo CD34+ selected allogeneic haematopoietic cell transplantation (HCT) provides favourable chronic graft-versus-host disease (GVHD)-free relapse-free survival but is limited by delayed immune reconstitution and early non-relapse mortality. High anti-thymocyte globulin (ATG) exposure after HCT has been associated with delayed CD4+ T-cell immune reconstitution, increased non-relapse mortality, and poor overall survival. METHODS: We report the final analysis of a single-centre, phase 2 trial investigating pharmacokinetic model-based ATG (targeting <20 AU × d/mL post-HCT exposure) in participants of any age undergoing ex vivo CD34+ selected allogeneic HCT after myeloablative conditioning for haematological malignancies. Two myeloablative conditioning regimens were used at the discretion of the treating physician: the chemotherapy-based regimen (target cumulative exposure of 65 mg × h/L busulfan, 140 mg/m2 melphalan, and 150 mg/m2 fludarabine) and a high-dose total-body irradiation-based regimen (included total-body irradiation [1375 cGy], thiotepa [10 mg/kg], and cyclophosphamide [100 mg/kg]). The primary objective was an improvement in CD4+ immune reconstitution (>50 cells per μL at two consecutive timepoints by day +100) in at least 32% of the per protocol population. This study was registered with ClinicalTrials.gov (NCT04872595) and is completed. FINDINGS: Between June 14, 2021, and Nov 28, 2023, we enrolled 59 participants with haematological malignancies. Among evaluable participants (n=56), the median age was 55 years (IQR 30-63), 34 (61%) were male, 22 (39%) were female, 44 (79%) had myeloid malignancies, and 44 (79%) had received chemotherapy-only myeloablative conditioning. The median estimated ATG exposure after HCT was 10 AU × d/mL (IQR 9-11). CD4+ immune reconstitution was reached in 39 (70%) of 56 participants, meeting the study's primary endpoint. The most common grade 3 or worse adverse events were infections (103 [40%] of 259 events) and oral or gastrointestinal events (44 [17%] of 259 events). Grade 5 adverse events occurred in three participants including secondary graft failure (n=1) and multi-organ failure (n=2), with a total of four treatment-related deaths among participants. INTERPRETATION: These results demonstrate that model-based ATG dosing promotes robust CD4+ immune reconstitution after ex vivo CD34+ selected allogeneic HCT, underscoring the potential of pharmacokinetically guided ATG as a strategy to optimise immune recovery in myeloablative, calcineurin inhibitor-free transplantation for haematological malignancies. FUNDING: US National Cancer Institute, Memorial Sloan Kettering Cancer Center.
引用
- Scordo M, Perales MA, Mauguen A, et al. Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study. Lancet Haematol. 2025. PMID: 41338864. doi:10.1016/S2352-3026(25)00293-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。